Stocks & Investing
Stocks and Investing
Stocks and Investing
Thu, December 22, 2022
[ Thu, Dec 22nd 2022
] - WOPRAI
[ Thu, Dec 22nd 2022
] - WOPRAI
[ Thu, Dec 22nd 2022
] - WOPRAI
[ Thu, Dec 22nd 2022
] - WOPRAI
Wed, December 21, 2022
[ Wed, Dec 21st 2022
] - WOPRAI
[ Wed, Dec 21st 2022
] - WOPRAI
[ Wed, Dec 21st 2022
] - WOPRAI
[ Wed, Dec 21st 2022
] - WOPRAI
[ Wed, Dec 21st 2022
] - WOPRAI
[ Wed, Dec 21st 2022
] - WOPRAI
[ Wed, Dec 21st 2022
] - WOPRAI
[ Wed, Dec 21st 2022
] - WOPRAI
[ Wed, Dec 21st 2022
] - WOPRAI
[ Wed, Dec 21st 2022
] - WOPRAI
[ Wed, Dec 21st 2022
] - WOPRAI
[ Wed, Dec 21st 2022
] - WOPRAI
[ Wed, Dec 21st 2022
] - WOPRAI
[ Wed, Dec 21st 2022
] - WOPRAI
[ Wed, Dec 21st 2022
] - WOPRAI
[ Wed, Dec 21st 2022
] - WOPRAI
[ Wed, Dec 21st 2022
] - WOPRAI
[ Wed, Dec 21st 2022
] - WOPRAI
[ Wed, Dec 21st 2022
] - WOPRAI
[ Wed, Dec 21st 2022
] - WOPRAI
[ Wed, Dec 21st 2022
] - WOPRAI
David Westenberg Upgraded (ADPT) to Buy and Increased Target to $14 on, Dec 21st, 2022
David Westenberg of Piper Sandler, Upgraded "Adaptive Biotechnologies Corporation" (ADPT) to Buy and Increased Target from $7.5 to $14 on, Dec 21st, 2022.
David has made no other calls on ADPT in the last 4 months.
There are 2 other peers that have a rating on ADPT. Out of the 2 peers that are also analyzing ADPT, 1 agrees with David's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Tejas Savant of "Morgan Stanley" Maintained at Hold with Decreased Target to $16 on, Monday, November 7th, 2022
This is the rating of the analyst that currently disagrees with David
- Dan Leonard of "Credit Suisse" Initiated at Sell and Held Target at $8 on, Thursday, August 25th, 2022
